Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial - Pratley, R E; Aroda, V R; Lingvay, I (Lancet Diabetes Endocrinol, 2018)